Large Cell Lung Neuroendocrine Carcinoma
Back to Diseases List
Associated Genetic Biomarkers
NCI Definition: A high grade malignant neoplasm that arises from the lung and is characterized by the presence of large neuroendocrine cells. It usually has an aggressive clinical course. 
There are 4 clinical trials for large cell lung neuroendocrine carcinoma, of which 2 are open and 2 are completed or closed. Of the trials that contain large cell lung neuroendocrine carcinoma as an inclusion criterion, 1 is phase 1/phase 2 (0 open) and 3 are phase 2 (2 open).
EGFR and SSTR2 are the most frequent gene inclusion criteria for large cell lung neuroendocrine carcinoma clinical trials .
Nivolumab, pen-221, and etoposide are the most common interventions in large cell lung neuroendocrine carcinoma clinical trials.
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.